

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 30, 2024

HCC38

RRID:CVCL_1267

Type: Cell Line

Proper Citation

(RRID:CVCL_1267)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1267

Proper Citation: (RRID:CVCL_1267)

Description: Cell line HCC38 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:9833771](#), [PMID:9865903](#), [PMID:11314036](#), [PMID:12800145](#), [PMID:14762065](#), [PMID:16959974](#), [PMID:17157791](#), [PMID:17932254](#), [PMID:19582160](#), [PMID:20070913](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21778573](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard L. and Gazdar A.F., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: miRNA expression profiling., Omics: Glycoproteome analysis by proteomics., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: CNV analysis., Omics: Array-based CGH., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: GrayJW breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell

line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC38

Synonyms: Hcc38, HCC-38, HCC 38, HCC0038, Hamon Cancer Center 38

Cross References: BTO:BTO:0005295, CLO:CLO_0003655, EFO:EFO_0001180, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:CRL-2314, BioGRID_ORCS_Cell_line:871, BioSample:SAMN03471264, BioSample:SAMN10987659, cancercellines:CVCL_1267, CCRID:1101HUM-PUMC000220, Cell_Model_Passport:SIDM00675, ChEMBL-Cells:ChEMBL3308578, ChEMBL-Targets:ChEMBL1075460, Cosmic:749717, Cosmic:904356, Cosmic:1018475, Cosmic:1047706, Cosmic:1136365, Cosmic:1235078, Cosmic:1287932, Cosmic:1430346, Cosmic:1460229, Cosmic:1518108, Cosmic:1603212, Cosmic:1935000, Cosmic:1995432, Cosmic:2009508, Cosmic:2164993, Cosmic-CLP:749717, DepMap:ACH-000276, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:749717, GEO:GSM149979, GEO:GSM149987, GEO:GSM149995, GEO:GSM185085, GEO:GSM185086, GEO:GSM217579, GEO:GSM344382, GEO:GSM344432, GEO:GSM350536, GEO:GSM378150, GEO:GSM533398, GEO:GSM533405, GEO:GSM537968, GEO:GSM783968, GEO:GSM827244, GEO:GSM847390, GEO:GSM847487, GEO:GSM844013, GEO:GSM854621, GEO:GSM854622, GEO:GSM854623, GEO:GSM854624, GEO:GSM854625, GEO:GSM887054, GEO:GSM888124, GEO:GSM1008902, GEO:GSM1053702, GEO:GSM1172967, GEO:GSM1172875, GEO:GSM1214580, GEO:GSM1215289, GEO:GSM1215291, GEO:GSM1215293, GEO:GSM1215294, GEO:GSM1215292, GEO:GSM1215290, GEO:GSM1215295, GEO:GSM1215296, GEO:GSM1374511, GEO:GSM1401651, GEO:GSM1669859, IARC_TP53:10268, IGRhCellID:HCC38, KCLB:9S0038, LiGeA:CCL_393, LINCS_HMS:50216, LINCS_LDP:LCL-1334, PharmacDB:HCC38_500_2019, PRIDE:PXD005295, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_1267, PubChem_Cell_line:CVCL_1267, Wikidata:Q54881712

ID: CVCL_1267

Originate from Same Individual: CVCL_1268

Ratings and Alerts

No rating or validation information has been found for HCC38.

No alerts have been found for HCC38.

Data and Source Information

Usage and Citation Metrics

We found 366 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Dibra D, et al. (2024) Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. *Science advances*, 10(7), eadk1835.

Gali A, et al. (2024) Protein kinase D drives the secretion of invasion mediators in triple-negative breast cancer cell lines. *iScience*, 27(2), 108958.

Massicano AVF, et al. (2023) [89Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models. *Cancers*, 15(10).

Tian Y, et al. (2023) Akt3 promotes cancer stemness in triple-negative breast cancer through YB1-Snail/Slug signaling axis. *Genes & diseases*, 10(2), 301.

Twomey JD, et al. (2023) Exploring the Role of Hypoxia-Inducible Carbonic Anhydrase IX (CAIX) in Circulating Tumor Cells (CTCs) of Breast Cancer. *Biomedicines*, 11(3).

Shrestha M, et al. (2023) CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer. *Oncogenesis*, 12(1), 29.

Limsakul P, et al. (2023) Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. *Cancers*, 15(2).

Ma Y, et al. (2023) LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling. *Oncogene*, 42(18), 1419.

Tunali G, et al. (2023) A positive feedback loop driven by fibronectin and IL-1 β sustains the inflammatory microenvironment in breast cancer. *Breast cancer research : BCR*, 25(1), 27.

Simoneau A, et al. (2023) Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer. *Molecular cancer therapeutics*, 22(2), 215.

Qu W, et al. (2023) Prognostic and Immunological Roles of CES2 in Breast Cancer and Potential Application of CES2-Targeted Fluorescent Probe DDAB in Breast Surgery. *International journal of general medicine*, 16, 1567.

Zeng Y, et al. (2023) Hsa_circ_0060467 promotes breast cancer liver metastasis by complexing with eIF4A3 and sponging miR-1205. *Cell death discovery*, 9(1), 153.

Kohabir KAV, et al. (2023) In Vitro CRISPR-Cas12a-Based Detection of Cancer-Associated TP53 Hotspot Mutations Beyond the crRNA Seed Region. *The CRISPR journal*, 6(2), 127.

Hikisz P, et al. (2023) Mechanistic Studies of Arene-Ruthenium(II) Complexes with Carbothioamidopyrazoles as Alternative Cancer Drugs. *Molecules* (Basel, Switzerland), 28(9).

Ma J, et al. (2023) CVAM: CNA Profile Inference of the Spatial Transcriptome Based on the VGAE and HMM. *Biomolecules*, 13(5).

Piemonte KM, et al. (2023) Disruption of CDK7 signaling leads to catastrophic chromosomal instability coupled with a loss of condensin-mediated chromatin compaction. *The Journal of biological chemistry*, 299(7), 104834.

Cao M, et al. (2023) An actin filament branching surveillance system regulates cell cycle progression, cytokinesis and primary ciliogenesis. *Nature communications*, 14(1), 1687.

Bhattacharya U, et al. (2023) Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. *Cancers*, 15(2).

Wang S, et al. (2023) Suppression of GCH1 Sensitizes Ovarian Cancer and Breast Cancer to PARP Inhibitor. *Journal of oncology*, 2023, 1453739.

Liu J, et al. (2023) PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity. *Nature communications*, 14(1), 2806.